Grail (GRAL) to Release Earnings on Tuesday

Grail (NASDAQ:GRAL) will likely be releasing its earnings data before the market opens on Tuesday, February 11th. Analysts expect Grail to post earnings of ($4.41) per share for the quarter.

Grail (NASDAQ:GRAL) last released its earnings results on Tuesday, November 12th. The company reported ($3.94) EPS for the quarter. The business had revenue of $28.65 million for the quarter. On average, analysts expect Grail to post $-65 EPS for the current fiscal year and $-15 EPS for the next fiscal year.

Grail Price Performance

Shares of Grail stock opened at $32.21 on Monday. Grail has a fifty-two week low of $12.33 and a fifty-two week high of $35.67. The business’s fifty day moving average is $21.72 and its two-hundred day moving average is $17.17.

Analyst Ratings Changes

A number of brokerages have issued reports on GRAL. Morgan Stanley initiated coverage on Grail in a research note on Wednesday, November 27th. They issued an “equal weight” rating and a $16.00 price target on the stock. Guggenheim initiated coverage on shares of Grail in a research report on Thursday, October 17th. They issued a “neutral” rating on the stock. Finally, Wolfe Research assumed coverage on shares of Grail in a report on Friday, November 15th. They issued a “peer perform” rating for the company.

Insider Buying and Selling

In other Grail news, CFO Aaron Freidin sold 30,452 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the completion of the sale, the chief financial officer now directly owns 268,277 shares in the company, valued at $3,761,243.54. The trade was a 10.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.